Your browser is no longer supported. Please, upgrade your browser.
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.95 Insider Own0.20% Shs Outstand154.16M Perf Week8.27%
Market Cap920.04M Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float135.46M Perf Month18.93%
Income-115.40M PEG- EPS next Q-0.26 Inst Own72.30% Short Float15.23% Perf Quarter162.56%
Sales47.80M P/S19.25 EPS this Y4.00% Inst Trans-10.58% Short Ratio1.80 Perf Half Y64.20%
Book/sh0.02 P/B271.75 EPS next Y20.00% ROA-89.00% Target Price8.57 Perf Year51.82%
Cash/sh0.67 P/C8.13 EPS next 5Y19.90% ROE- 52W Range1.38 - 6.29 Perf YTD57.54%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-84.10% 52W High-13.54% Beta2.88
Dividend %- Quick Ratio- Sales past 5Y29.10% Gross Margin94.40% 52W Low293.84% ATR0.39
Employees140 Current Ratio1.40 Sales Q/Q-18.60% Oper. Margin- RSI (14)61.83 Volatility9.75% 8.33%
OptionableYes Debt/Eq22.28 EPS Q/Q13.50% Profit Margin- Rel Volume0.49 Prev Close5.53
ShortableYes LT Debt/Eq10.14 EarningsMay 06 BMO Payout- Avg Volume11.49M Price5.43
Recom2.10 SMA2017.90% SMA5017.48% SMA20072.59% Volume5,593,763 Change-1.63%
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Jul-07-20 02:43PM  
Jul-02-20 07:00AM  
Jun-18-20 08:53AM  
Jun-15-20 07:43AM  
Jun-10-20 02:00PM  
Jun-09-20 04:15PM  
Jun-08-20 03:40PM  
Jun-06-20 03:01AM  
Jun-02-20 07:15AM  
Jun-01-20 04:01PM  
May-28-20 04:15PM  
May-27-20 11:35PM  
May-26-20 07:00AM  
May-19-20 03:18PM  
May-18-20 02:47PM  
May-15-20 07:53AM  
May-13-20 11:30AM  
May-11-20 02:45PM  
May-07-20 01:07PM  
May-06-20 07:31PM  
May-05-20 07:00AM  
May-04-20 04:15PM  
Apr-29-20 01:17PM  
Apr-27-20 05:50PM  
Apr-26-20 07:51AM  
Apr-22-20 07:00AM  
Apr-21-20 12:19PM  
Apr-20-20 09:06AM  
Apr-15-20 09:36AM  
Apr-14-20 06:29PM  
Apr-13-20 12:27PM  
Apr-10-20 02:06PM  
Apr-09-20 05:52PM  
Apr-08-20 07:00AM  
Apr-03-20 06:04PM  
Apr-02-20 12:28PM  
Apr-01-20 08:18AM  
Mar-30-20 07:00AM  
Mar-17-20 06:41AM  
Mar-16-20 07:10AM  
Mar-13-20 02:30PM  
Mar-10-20 12:00PM  
Mar-09-20 08:03AM  
Mar-05-20 08:25AM  
Mar-03-20 07:00AM  
Mar-02-20 04:15PM  
Feb-28-20 09:30AM  
Feb-27-20 12:30PM  
Feb-25-20 03:25PM  
Feb-20-20 07:00AM  
Feb-18-20 07:00AM  
Feb-10-20 06:25AM  
Feb-06-20 07:00AM  
Feb-05-20 11:52AM  
Feb-03-20 07:00AM  
Jan-23-20 01:02PM  
Jan-15-20 07:00AM  
Jan-10-20 08:54AM  
Jan-06-20 07:00AM  
Jan-03-20 07:00AM  
Dec-31-19 03:15PM  
Dec-12-19 02:34PM  
Dec-11-19 03:04PM  
Dec-04-19 10:02AM  
Nov-21-19 07:49AM  
Nov-20-19 02:18PM  
Nov-18-19 04:01PM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stonehouse Jon PPresident & CEONov 18Buy1.4550,00072,500778,086Nov 18 04:17 PM
Sniecinski MeganChief Business OfficerNov 18Buy1.4545,00065,25045,000Nov 18 04:16 PM
LEE KENNETH B JRDirectorNov 18Buy1.455,0007,25015,252Nov 18 04:14 PM
INGRAM ROBERT ALEXANDERDirectorNov 18Buy1.4520,00029,00048,088Nov 18 04:12 PM
Hutson Nancy JDirectorNov 18Buy1.4510,00014,50053,046Nov 18 04:10 PM
HEGGIE THERESADirectorNov 18Buy1.455,0007,2506,672Nov 18 04:08 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 18Buy1.4520,00029,000102,061Nov 18 04:05 PM
Babu Yarlagadda SSenior VP - Drug DiscoveryNov 18Buy1.4525,00036,250155,587Nov 18 04:03 PM
ASELAGE STEVEDirectorNov 18Buy1.4515,00021,75021,672Nov 18 04:01 PM